Skip to main content
. 2020 Mar 21;30(3):313–324. doi: 10.4014/jmb.2003.03011

Table 1.

List of candidate therapeutic agents for SARS-CoV-2 treatment.

Candidate therapeutic Market name Manufacturer Target disease EC50(COVID-19) Status of clinical trials
Favipiravir (T-705) Avigan Toyama Influenza 61.88 μM [41] Under clinical trial for COVID-19 (ChiCTR2000029548)
graphic file with name JMB-30-3-313-i1.jpg
Remdesivir (GS-5734) graphic file with name JMB-30-3-313-i2.jpg Gilead Ebola 0.77 μM [41] Phase II clinical trial for Ebola (NCT03719586); Under phase III clinical trials for COVID-19 (NCT04252664)
Chloroquine/Hydroxychloroquine Aralen/Plaquenil Sanofi Malaria 1.13 μM [41] Under clinical trials for COVID-19 (a)
graphic file with name JMB-30-3-313-i3.jpg
Lopinavir and Ritonavir Kaletra Abbott HIV −b Under clinical trials for SARS [59] Under clinical trial for COVID-19 (ChiCTR2000029539)
graphic file with name JMB-30-3-313-i4.jpg
Pegylated interferon with ribavirin Virazole Valeant HBV, HCV 109 μM [41] Under clinical trial for COVID-19 (ChiCTR2000029387)
graphic file with name JMB-30-3-313-i5.jpg

aChiCTR2000029939, ChiCTR2000029935, ChiCTR2000029899, ChiCTR2000029898, ChiCTR2000029868, ChiCTR2000029837, ChiCTR2000029826, ChiCTR2000029803, ChiCTR2000029762, ChiCTR2000029761, ChiCTR2000029760, ChiCTR2000029740, ChiCTR2000029609, ChiCTR2000029559, and ChiCTR2000029542

bUndetermined